Oritavancin Diphosphate is a next-generation lipoglycopeptide antibiotic belonging to the vancomycin class, indicated for the treatment of serious Gram-positive bacterial infections, including those caused… Read more
Oritavancin Diphosphate is a next-generation lipoglycopeptide antibiotic belonging to the vancomycin class, indicated for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. This compound functions by inhibiting bacterial cell wall synthesis through binding to the D-Ala-D-Ala termini of peptidoglycan precursors. To support accurate analytical testing and rigorous quality control within pharmaceutical laboratories, access to high-quality reference standards, metabolites, and impurities is essential. These compounds facilitate precise impurity profiling and method validation, ensuring compliance with regulatory standards throughout the drug development lifecycle. Additionally, stable isotope labelled compounds are critical for sensitive quantitative analysis, such as mass spectrometry-based assays, allowing for the precise tracking of the drug and its related substances in biological matrices during pharmacokinetic and metabolic studies.